Kilitch Drugs

{
  "main_header": {
    "sid": 189669,
    "name": "Kilitch Drugs",
    "stock_name": "Kilitch Drugs",
    "full_name": "Kilitch Drugs (India) Ltd",
    "name_url": "stocks-analysis/kilitch-drugs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "334.65",
    "chg": 10.8,
    "chgp": "3.33%",
    "dir": 1,
    "prev_price": "323.85",
    "mcapval": "577.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524500,
    "symbol": "KILITCH",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE729D01010",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "13.26 k",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/kilitch-drugs-189669-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Kilitch Drugs (India) Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/kilitch-drugs-india-ltd-is-rated-sell-3803095",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/KilitchDrugsInd_mojoScore_3803095.png",
        "date": "2026-01-24 10:10:03",
        "description": "Kilitch Drugs (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 24 January 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Why is Kilitch Drugs (India) Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-kilitch-drugs-india-ltd-fallingrising-3797147",
        "imagepath": "",
        "date": "2026-01-21 00:49:22",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Performance and Market Context</strong></p>\n<p>The stock has been under pressure for the past three consecutive days, registering a cumulative loss of 5.47% during this period. This underperformance is more pronounced when compared to the Pharmaceuticals &amp; Drugs sector, which itself declined by 2.1% on the same day. Kilitch Drugs also lagged behind the sector by approximately 1% in today’s trading session, signalling a relatively weaker investor appetite for the stock amid sector-wide challenges.</p>\n<p>When viewed against the broader market benchmark, the Sensex, Kilitch Drugs’ performance remains subdued. Over the past week, the stock fell by 4.94%, significantly underperforming the Sensex’s 1.73% decline. Year-to-date, the stock has dropped 7.37%, almost double the Sensex..."
      },
      {
        "title": "Kilitch Drugs (India) Ltd Faces Bearish Momentum Amid Technical Downturn",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kilitch-drugs-india-ltd-faces-bearish-momentum-amid-technical-downturn-3782472",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/KilitchDrugsInd_technicaldot_3782472.png",
        "date": "2026-01-06 08:04:14",
        "description": "Kilitch Drugs (India) Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. Despite recent short-term gains, the stock’s technical parameters have deteriorated, prompting a downgrade in its Mojo Grade to Sell as of 1 September 2025. This article analyses the evolving price momentum, technical indicator signals, and broader market context to provide a comprehensive view of the stock’s outlook."
      },
      {
        "title": "Kilitch Drugs (India) Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/kilitch-drugs-india-ltd-is-rated-sell-3778866",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/KilitchDrugsInd_mojoScore_3778866.png",
        "date": "2026-01-02 10:10:03",
        "description": "Kilitch Drugs (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Kilitch Drugs (India) Ltd: Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kilitch-drugs-india-ltd-technical-momentum-shifts-amid-mixed-market-signals-3775599",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/KilitchDrugsInd_technicaldot_3775599.png",
        "date": "2025-12-31 08:01:34",
        "description": "Kilitch Drugs (India) Ltd has experienced a nuanced shift in its technical momentum as it navigates a complex market environment. Recent data reveals a transition from a bearish to a mildly bearish trend, with key indicators such as MACD, RSI, and moving averages signalling a cautious outlook for investors in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Kilitch Drugs Sees Revision in Market Evaluation Amidst Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/kilitch-drugs-downgraded-to-sell-by-marketsmojo-amid-weak-financial-and-technical-signals-3765649",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/KilitchDrugs_mojoScore_3765649.png",
        "date": "2025-12-22 10:10:04",
        "description": "Kilitch Drugs, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a more cautious analytical perspective. This shift follows a detailed review of the company’s financial and technical parameters, highlighting challenges in profitability and market momentum despite some stable valuation aspects."
      },
      {
        "title": "Kilitch Drugs (India) Sees Shift in Technical Momentum Amid Market Volatility",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kilitch-drugs-faces-bearish-momentum-amid-technical-downturn-3752641",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/KilitchDrugsInd_technicaldot_3752641.png",
        "date": "2025-12-09 08:02:55",
        "description": "Kilitch Drugs (India), a player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting evolving market dynamics and investor sentiment. Recent data reveals a transition in key technical indicators, signalling a more cautious outlook as the stock navigates a challenging environment."
      },
      {
        "title": "Is Kilitch Drugs technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-kilitch-drugs-technically-bullish-or-bearish-3747608",
        "imagepath": "",
        "date": "2025-12-05 08:23:26",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Overview of Kilitch Drugs’ Current Market Position</strong></p>\n<p>Kilitch Drugs is trading at ₹343.25, marginally above its previous close of ₹341.80. The stock’s 52-week range spans from ₹271.30 to ₹500.05, indicating significant volatility over the past year. Today’s intraday movement saw a high of ₹360.00 and a low of ₹337.95, reflecting some short-term price fluctuations.</p>\n<p>While the stock price remains comfortably above its yearly low, it is still well below the 52-week high, suggesting that the stock has not regained its peak momentum. This price behaviour is an important backdrop when analysing the technical indicators.</p>\n<p><strong>Technical Trend and Moving Averages</strong></p>\n<p>The overall technical trend for Kilitch Drugs recently shifted from bearish to mildly bearish ..."
      },
      {
        "title": "Kilitch Drugs (India) Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/kilitch-drugs-india-technical-momentum-shifts-amid-mixed-market-signals-3747477",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/KilitchDrugsInd_technicaldot_3747477.png",
        "date": "2025-12-05 08:01:12",
        "description": "Kilitch Drugs (India) has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish indicators across multiple timeframes. Recent market data reveals a subtle transition in price dynamics, with key technical parameters signalling a cautious outlook for the pharmaceutical company amid broader sector trends."
      }
    ],
    "total": 272,
    "sid": "189669",
    "stock_news_url": "https://www.marketsmojo.com/news/kilitch-drugs-india-189669"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "15-Jan-2026",
      "details": "We are submitting herewith the certificate under regulation74(5) received from our RTA",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "27-Dec-2025",
      "details": "Trading window will be closed with effect from 1st January 2026 till expiry of 48 hours from the declaration of unaudited financial results of the company for the quarter ended 31st December 2025",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "15-Nov-2025",
      "details": "We are hereby submitting the copy publication of extract of financial results for the quarter ended 30th September 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Kilitch Drugs (India) Ltd has declared <strong>5%</strong> dividend, ex-date: 20 Sep 19",
          "dt": "2019-09-20",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Kilitch Drugs (India) Ltd has announced <strong>2:23</strong> rights issue, ex-date: 15 Jul 25",
          "dt": "2025-07-15",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}

News and Views

Kilitch Drugs (India) Ltd is Rated Sell

2026-01-24 10:10:03

Kilitch Drugs (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 24 January 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Why is Kilitch Drugs (India) Ltd falling/rising?

2026-01-21 00:49:22

Recent Price Performance and Market Context

The stock has been under pressure for the past three consecutive days, registering a cumulative loss of 5.47% during this period. This underperformance is more pronounced when compared to the Pharmaceuticals & Drugs sector, which itself declined by 2.1% on the same day. Kilitch Drugs also lagged behind the sector by approximately 1% in today’s trading session, signalling a relatively weaker investor appetite for the stock amid sector-wide challenges.

When viewed against the broader market benchmark, the Sensex, Kilitch Drugs’ performance remains subdued. Over the past week, the stock fell by 4.94%, significantly underperforming the Sensex’s 1.73% decline. Year-to-date, the stock has dropped 7.37%, almost double the Sensex...

Read full news article

Kilitch Drugs (India) Ltd Faces Bearish Momentum Amid Technical Downturn

2026-01-06 08:04:14

Kilitch Drugs (India) Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. Despite recent short-term gains, the stock’s technical parameters have deteriorated, prompting a downgrade in its Mojo Grade to Sell as of 1 September 2025. This article analyses the evolving price momentum, technical indicator signals, and broader market context to provide a comprehensive view of the stock’s outlook.

Read full news article

Kilitch Drugs (India) Ltd is Rated Sell

2026-01-02 10:10:03

Kilitch Drugs (India) Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 September 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Kilitch Drugs (India) Ltd: Technical Momentum Shifts Amid Mixed Market Signals

2025-12-31 08:01:34

Kilitch Drugs (India) Ltd has experienced a nuanced shift in its technical momentum as it navigates a complex market environment. Recent data reveals a transition from a bearish to a mildly bearish trend, with key indicators such as MACD, RSI, and moving averages signalling a cautious outlook for investors in the Pharmaceuticals & Biotechnology sector.

Read full news article

Kilitch Drugs Sees Revision in Market Evaluation Amidst Mixed Financial Signals

2025-12-22 10:10:04

Kilitch Drugs, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a more cautious analytical perspective. This shift follows a detailed review of the company’s financial and technical parameters, highlighting challenges in profitability and market momentum despite some stable valuation aspects.

Read full news article

Kilitch Drugs (India) Sees Shift in Technical Momentum Amid Market Volatility

2025-12-09 08:02:55

Kilitch Drugs (India), a player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting evolving market dynamics and investor sentiment. Recent data reveals a transition in key technical indicators, signalling a more cautious outlook as the stock navigates a challenging environment.

Read full news article

Is Kilitch Drugs technically bullish or bearish?

2025-12-05 08:23:26

Overview of Kilitch Drugs’ Current Market Position

Kilitch Drugs is trading at ₹343.25, marginally above its previous close of ₹341.80. The stock’s 52-week range spans from ₹271.30 to ₹500.05, indicating significant volatility over the past year. Today’s intraday movement saw a high of ₹360.00 and a low of ₹337.95, reflecting some short-term price fluctuations.

While the stock price remains comfortably above its yearly low, it is still well below the 52-week high, suggesting that the stock has not regained its peak momentum. This price behaviour is an important backdrop when analysing the technical indicators.

Technical Trend and Moving Averages

The overall technical trend for Kilitch Drugs recently shifted from bearish to mildly bearish ...

Read full news article

Kilitch Drugs (India) Technical Momentum Shifts Amid Mixed Market Signals

2025-12-05 08:01:12

Kilitch Drugs (India) has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish indicators across multiple timeframes. Recent market data reveals a subtle transition in price dynamics, with key technical parameters signalling a cautious outlook for the pharmaceutical company amid broader sector trends.

Read full news article

View All News